Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up

ConclusionIn this prospective, open-label, single-arm study, the standalone implantation of two second-generation trabecular micro-bypass stents in OAG patients on 1 preoperative medication resulted in IOP reduction to ≤15 mmHg and elimination of medication through 18 months, with favorable safety.Trial RegistrationClinicalTrials.gov identifier, NCT02868190.FundingGlaukos Corporation, San Clemente, CA.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research